# A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer

> **NCT01684215** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 61 (actual)

## Conditions studied

- Neoplasms
- Breast Neoplasms

## Interventions

- **DRUG:** PD-0332991
- **DRUG:** PD-0332991
- **DRUG:** letrozole
- **DRUG:** PD-0332991
- **DRUG:** letrozole

## Key facts

- **NCT ID:** NCT01684215
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-19
- **Primary completion:** 2016-03-04
- **Final completion:** 2018-10-25
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01684215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01684215, "A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01684215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*